Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Pantaleo

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
ESMO Open|August 9, 2024
TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma GroupC Fabbroni, G Grignani, B Vincenzi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2025
Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma GroupL D'Ambrosio, A Merlini, A Brunello, et al.
ESMO Open|June 5, 2021
Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of expertsS Stacchiotti, A B Miah, A M Frezza, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
ESMO Open|August 9, 2024
TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma GroupC Fabbroni, G Grignani, B Vincenzi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2025
Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma GroupL D'Ambrosio, A Merlini, A Brunello, et al.
ESMO Open|June 5, 2021
Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of expertsS Stacchiotti, A B Miah, A M Frezza, et al.
Pageof 4